Retrospective Analysis of PET Brain Imaging in Chronic Cancer Pain

FDG PET Imaging Study of Brain Metabolic Change in Chronic Cancer Pain Patient: a Retrospective Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04537845

Enrollment

119

Registered

2020-09-03

Start date

2020-03-02

Completion date

2020-08-08

Last updated

2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Pain

Brief summary

Cancer pain deteriorated in quality of life and related with numerous psychosocial problems. Over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management. The 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images can provide quantitative results in clinical oncology. As a functional neuroimaging, the PET evidently provided anatomical activated regions, size, and spatial extent information. In this retrospective study, we use FDG-PET to investigate changes concerning the glucose metabolism in the brain with or without cancer pain.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* cancer patient

Exclusion criteria

* no brain metastasis

Design outcomes

Primary

Measure	Time frame	Description
Find the location of brain metabolic changes, pain scale	12 months	This retrospective analysis only compare image and clinical record including pain scale

Countries

Taiwan

Outcome results